These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24092920)

  • 1. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
    Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
    J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
    Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
    Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
    Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY
    Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
    Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY
    Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
    Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
    PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.
    Axelrod MJ; Mendez RE; Khalil A; Leimgruber SS; Sharlow ER; Capaldo B; Conaway M; Gioeli DG; Weber MJ; Jameson MJ
    Head Neck; 2015 Dec; 37(12):1722-32. PubMed ID: 24986420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
    Kalra N; Zhang J; Yu Y; Ho M; Merino M; Cao L; Hassan R
    Int J Cancer; 2012 Nov; 131(9):2143-52. PubMed ID: 22323052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
    Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
    MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
    Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
    Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
    Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
    Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
    Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
    Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.